129 related articles for article (PubMed ID: 24920858)
1. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome.
Sawai S; Satoh M; Mori M; Misawa S; Sogawa K; Kazami T; Ishibashi M; Beppu M; Shibuya K; Ishige T; Sekiguchi Y; Noda K; Sato K; Matsushita K; Kodera Y; Nomura F; Kuwabara S
Neurology; 2014 Jul; 83(2):113-7. PubMed ID: 24920858
[TBL] [Abstract][Full Text] [Related]
2. Are ERM (ezrin/radixin/moesin) proteins targets for autoantibodies in demyelinating neuropathies?
Miyaji K; Shahrizaila N; Umapathi T; Chan YC; Hirata K; Yuki N
Hum Immunol; 2014 Nov; 75(11):1089-91. PubMed ID: 25286001
[TBL] [Abstract][Full Text] [Related]
3. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome.
Miyaji K; Devaux J; Yuki N
Neurology; 2014 Dec; 83(24):2314. PubMed ID: 25488994
[No Abstract] [Full Text] [Related]
4. [Guillain-Barré syndrome following cytomegalovirus infection with increased level of antibody against moesin-a case report].
Shiga Y; Shimoe Y; Chigusa M; Kusunoki S; Mori M; Kuriyama M
Rinsho Shinkeigaku; 2018 Jun; 58(6):385-389. PubMed ID: 29863101
[TBL] [Abstract][Full Text] [Related]
5. [Target Molecule for a Demyelinating Type of Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyneuropathy].
Mori M
Brain Nerve; 2015 Nov; 67(11):1359-69. PubMed ID: 26560951
[TBL] [Abstract][Full Text] [Related]
6. The role of cytomegalovirus, Haemophilus influenzae and Epstein Barr virus in Guillain Barre syndrome.
Nafissi S; Vahabi Z; Sadeghi Ghahar M; Amirzargar AA; Naderi S
Acta Med Iran; 2013 Jul; 51(6):372-6. PubMed ID: 23852841
[TBL] [Abstract][Full Text] [Related]
7. Ranvier revisited: novel nodal antigens stimulate interest in GBS pathogenesis.
Willison H; Scherer SS
Neurology; 2014 Jul; 83(2):106-8. PubMed ID: 24920859
[No Abstract] [Full Text] [Related]
8. [Guillain-Barré syndrome with high titers of anti-GM2 and anti-GalNAc-GD1a antibody following cytomegalovirus hepatitis].
Shimoya K; Ohnishi A; Hashimoto T; Yuki N
Rinsho Shinkeigaku; 1997 Feb; 37(2):106-10. PubMed ID: 9164140
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Guillain-Barre syndrome in children: results from a Mexican population.
Nachamkin I; Arzarte Barbosa P; Ung H; Lobato C; Gonzalez Rivera A; Rodriguez P; Garcia Briseno A; Cordero LM; Garcia Perea L; Perez JC; Ribera M; Aldama PC; Guitérrez GD; Sarnat LF; García MR; Veitch J; Fitzgerald C; Cornblath DR; Rodriguez Pinto M; Griffin JW; Willison HJ; Asbury AK; McKhann GM
Neurology; 2007 Oct; 69(17):1665-71. PubMed ID: 17898327
[TBL] [Abstract][Full Text] [Related]
10. Nodal proteins are target antigens in Guillain-Barré syndrome.
Devaux JJ; Odaka M; Yuki N
J Peripher Nerv Syst; 2012 Mar; 17(1):62-71. PubMed ID: 22462667
[TBL] [Abstract][Full Text] [Related]
11. Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study.
Sinha S; Prasad KN; Jain D; Pandey CM; Jha S; Pradhan S
Clin Microbiol Infect; 2007 Mar; 13(3):334-7. PubMed ID: 17391394
[TBL] [Abstract][Full Text] [Related]
12. Primary cytomegalovirus infection in patients with Guillain-Barré syndrome.
Steininger C; Seiser A; Gueler N; Puchhammer-Stöckl E; Aberle SW; Stanek G; Popow-Kraupp T
J Neuroimmunol; 2007 Feb; 183(1-2):214-9. PubMed ID: 17184845
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome.
Ang CW; Jacobs BC; Brandenburg AH; Laman JD; van der Meché FG; Osterhaus AD; van Doorn PA
Neurology; 2000 Apr; 54(7):1453-8. PubMed ID: 10751257
[TBL] [Abstract][Full Text] [Related]
14. Author response.
Sawai S; Mori M; Kuwabara S
Neurology; 2014 Dec; 83(24):2314; discussion 2314-5. PubMed ID: 25632420
[No Abstract] [Full Text] [Related]
15. The Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.
Ziganshin RH; Ivanova OM; Lomakin YA; Belogurov AA; Kovalchuk SI; Azarkin IV; Arapidi GP; Anikanov NA; Shender VO; Piradov MA; Suponeva NA; Vorobyeva AA; Gabibov AG; Ivanov VT; Govorun VM
Mol Cell Proteomics; 2016 Jul; 15(7):2366-78. PubMed ID: 27143409
[TBL] [Abstract][Full Text] [Related]
16. The pathogenic relevance of α
Dong C; Palladino SP; Helton ES; Ubogu EE
Acta Neuropathol; 2016 Nov; 132(5):739-752. PubMed ID: 27460017
[TBL] [Abstract][Full Text] [Related]
17. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.
Yuki N
Lancet Infect Dis; 2001 Aug; 1(1):29-37. PubMed ID: 11871407
[TBL] [Abstract][Full Text] [Related]
18. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study.
Orlikowski D; Porcher R; Sivadon-Tardy V; Quincampoix JC; Raphaël JC; Durand MC; Sharshar T; Roussi J; Caudie C; Annane D; Rozenberg F; Leruez-Ville M; Gaillard JL; Gault E
Clin Infect Dis; 2011 Apr; 52(7):837-44. PubMed ID: 21427390
[TBL] [Abstract][Full Text] [Related]
19. Post-CMV Guillain-Barré Syndrome with Anti-GM2 Antibodies: Two Cases and a Review of the Literature.
Manaud A; Geraudie A; Viguier A; Mengelle C; Fortenfant F; Baudou E; Cheuret E
Neuropediatrics; 2022 Aug; 53(4):235-238. PubMed ID: 35716658
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in northeastern China.
Ye Y; Wang K; Deng F; Xing Y
Muscle Nerve; 2013 Jan; 47(1):68-71. PubMed ID: 23042578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
